Gavin O'mahony
AstraZeneca R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif.
Journal: ChemMedChem
Published: November 19, 2025
N-Biphenyl Pyrrolinones and Dibenzofurans as RNA-Binding Protein LIN28 Inhibitors Disrupting the LIN28-Let-7 Interaction.
Journal: ACS medicinal chemistry letters
Published: August 03, 2023
Correction to "Designing Selective Drug-like Molecular Glues for the Glucocorticoid Receptor/14-3-3 Protein-Protein Interaction".
Journal: Journal of medicinal chemistry
Published: January 28, 2023
Designing Selective Drug-like Molecular Glues for the Glucocorticoid Receptor/14-3-3 Protein-Protein Interaction.
Journal: Journal of medicinal chemistry
Published: December 09, 2022
Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.
Journal: ACS medicinal chemistry letters
Published: December 22, 2021
A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes.
Journal: STAR protocols
Published: August 19, 2021
Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes.
Journal: Current research in pharmacology and drug discovery
Published: May 04, 2021
Design of Drug-Like Protein-Protein Interaction Stabilizers Guided By Chelation-Controlled Bioactive Conformation Stabilization.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: April 03, 2020
Phosphorylated full-length Tau interacts with 14-3-3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14-3-3 dimer.
Journal: The FEBS journal
Published: November 04, 2019
Last Updated: 09/26/2026